Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Nurix Therapeutics, Inc.NRIX · Entity 1156 | Director | May 15, 2026 | May 15, 2026 |
| Rapport Therapeutics, Inc.RAPP · Entity 4394 | Director | June 10, 2026 | June 10, 2026 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | SVP & Chief Accounting Officer | February 26, 2021 | March 02, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Nurix Therapeutics, Inc.
Report date May 15, 2026 · Filed May 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.86 · Expires 2036-05-14 | Direct | 31,250 |
Reported balance
After 2026-05-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-15 · Grant · Acquired 31,250 · Balance 31,250 F1: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date.
Rapport Therapeutics, Inc.
Report date June 10, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.21 · Expires 2036-06-10 | Direct | 15,200 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 15,200 · Balance 15,200 F1: The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.
VERTEX PHARMACEUTICALS INC / MA
Report date February 26, 2021 · Filed March 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,884 |
Ending reported balance
After 2021-03-01 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2021-02-26 · Tax withholding · Disposed 2,218 · Balance 12,666 Row 2 · 2021-03-01 · Sale · Disposed 1,026 · Balance 11,640 F1: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F2: Open market sales reported on this line occurred at a weighted average price of $210.13 (range $209.93 to $210.77). F3: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Row 3 · 2021-03-01 · Sale · Disposed 610 · Balance 11,030 F1: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4: Open market sales reported on this line occurred at a weighted average price of $211.45 (range $210.96 to $211.95). Row 4 · 2021-03-01 · Sale · Disposed 915 · Balance 10,115 F1: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5: Open market sales reported on this line occurred at a weighted average price of $212.51 (range $211.96 to $212.85). Row 5 · 2021-03-01 · Sale · Disposed 231 · Balance 9,884 F1: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6: Open market sales reported on this line occurred at a weighted average price of $213.12 (range $212.96 to $213.27). |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 169 |
Reported balance
Holding disclosure · report date 2021-02-26 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 169 |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $210.13 (range $209.93 to $210.77).
F3: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4: Open market sales reported on this line occurred at a weighted average price of $211.45 (range $210.96 to $211.95).
F5: Open market sales reported on this line occurred at a weighted average price of $212.51 (range $211.96 to $212.85).
F6: Open market sales reported on this line occurred at a weighted average price of $213.12 (range $212.96 to $213.27).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 23, 2015 Filed Feb 25, 2015 21:23 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 860 | $0.00 Strike: $83.36 | $0.00 |
DisclosureSEC source: 0001209191-15-018504 · doc4.xml · derivative · entry 5 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,593 Underlying: Common Stock · 860 shares Expires 2023-07-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 07/30/2013. Read SEC document |
| February 23, 2015 Filed Feb 25, 2015 21:23 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,150 | $119.85 | $257,677.50 |
DisclosureSEC source: 0001209191-15-018504 · doc4.xml · nonDerivative · entry 3 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,625 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. Read SEC document |
| February 23, 2015 Filed Feb 25, 2015 21:23 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,290 | $77.31 | $99,729.90 |
DisclosureSEC source: 0001209191-15-018504 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,775 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2015 Filed Feb 25, 2015 21:23 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 860 | $83.36 | $71,689.60 |
DisclosureSEC source: 0001209191-15-018504 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,485 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2015 Filed Feb 20, 2015 21:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,449 | $113.16 | $163,968.84 |
DisclosureSEC source: 0001209191-15-016687 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,625 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $113.16 (range $113.03 to $113.30). Read SEC document |
| February 18, 2015 Filed Feb 20, 2015 21:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,988 | $112.71 | $224,067.48 |
DisclosureSEC source: 0001209191-15-016687 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,074 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $112.71 (range $112.02 to $113.00). F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 05, 2015 Filed Feb 6, 2015 22:41 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 1,688 | $0.00 Strike: $45.11 | $0.00 |
DisclosureSEC source: 0001209191-15-010443 · doc4.xml · derivative · entry 6 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 Underlying: Common Stock · 1,688 shares Expires 2023-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/05/2013. Read SEC document |
| February 05, 2015 Filed Feb 6, 2015 22:41 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 388 | $110.76 | $42,974.88 |
DisclosureSEC source: 0001209191-15-010443 · doc4.xml · nonDerivative · entry 4 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,062 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $110.76 (range $110.50 to $111.03). Read SEC document |
| February 05, 2015 Filed Feb 6, 2015 22:41 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 900 | $109.74 | $98,766.00 |
DisclosureSEC source: 0001209191-15-010443 · doc4.xml · nonDerivative · entry 3 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,450 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $109.74 (range $109.45 to $110.13). Read SEC document |
| February 05, 2015 Filed Feb 6, 2015 22:41 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 400 | $108.81 | $43,524.00 |
DisclosureSEC source: 0001209191-15-010443 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,350 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $108.81 (range $108.27 to $109.10). F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 05, 2015 Filed Feb 6, 2015 22:41 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,688 | $45.11 | $76,145.68 |
DisclosureSEC source: 0001209191-15-010443 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2015 Filed Feb 4, 2015 21:53 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 938 | $0.00 Strike: $38.80 | $0.00 |
DisclosureSEC source: 0001209191-15-009472 · doc4.xml · derivative · entry 12 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 938 shares Expires 2021-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Fully vested. Read SEC document |
| February 03, 2015 Filed Feb 4, 2015 21:53 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $111.32 | $11,132.00 |
DisclosureSEC source: 0001209191-15-009472 · doc4.xml · nonDerivative · entry 9 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,187 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. Read SEC document |
| February 03, 2015 Filed Feb 4, 2015 21:53 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $109.50 | $10,950.00 |
DisclosureSEC source: 0001209191-15-009472 · doc4.xml · nonDerivative · entry 8 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,287 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. Read SEC document |
| February 03, 2015 Filed Feb 4, 2015 21:53 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 300 | $108.16 | $32,448.00 |
DisclosureSEC source: 0001209191-15-009472 · doc4.xml · nonDerivative · entry 7 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,387 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $108.16 (range $108.03 to $108.40). Read SEC document |
| February 03, 2015 Filed Feb 4, 2015 21:53 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 438 | $107.04 | $46,883.52 |
DisclosureSEC source: 0001209191-15-009472 · doc4.xml · nonDerivative · entry 6 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,687 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $107.04 (range $106.77 to $107.45). Read SEC document |
| February 03, 2015 Filed Feb 4, 2015 21:53 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 938 | $38.80 | $36,394.40 |
DisclosureSEC source: 0001209191-15-009472 · doc4.xml · nonDerivative · entry 5 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,125 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2015 Filed Feb 5, 2015 22:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option (right to buy) · Derivative | 20,625 | $0.00 Strike: $109.14 | $0.00 |
DisclosureSEC source: 0001209191-15-009903 · doc4.xml · derivative · entry 3 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,625 Underlying: Common Stock · 20,625 shares Expires 2025-02-02 F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/03/2015. Read SEC document |
| February 03, 2015 Filed Feb 5, 2015 22:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 6,875 | $0.01 | $68.75 |
DisclosureSEC source: 0001209191-15-009903 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,062 F1 · shares: Performance-based restricted stock award that will vest as to (i) 50% of the shares on the earlier to occur of (a) the attainment of a specified level of net product sales in the United States of lumacaftor in combination with ivacaftor over four calendar quarters and (b) the announcement of the results of a clinical trial establishing proof-of-concept for a next generation CFTR corrector and (ii) 50% of the shares on the earlier to occur of (a) the attainment of a specified level of net product sales outside of the United States of lumacaftor in combination with ivacaftor over four calendar quarters and (b) the announcement of the results from a successful pivotal clinical trial for a non-cystic fibrosis drug candidate sufficient to support the filing of an NDA. Read SEC document |
| February 02, 2015 Filed Feb 4, 2015 21:53 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 1,125 | $0.00 Strike: $37.86 | $0.00 |
DisclosureSEC source: 0001209191-15-009472 · doc4.xml · derivative · entry 11 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 1,125 shares Expires 2022-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/02/2012. Read SEC document |
| February 02, 2015 Filed Feb 4, 2015 21:53 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 157 | $110.76 | $17,389.32 |
DisclosureSEC source: 0001209191-15-009472 · doc4.xml · nonDerivative · entry 4 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,187 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $110.76 (range $110.74 to $110.80). Read SEC document |
| February 02, 2015 Filed Feb 4, 2015 21:53 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 668 | $109.89 | $73,406.52 |
DisclosureSEC source: 0001209191-15-009472 · doc4.xml · nonDerivative · entry 3 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,344 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $109.89 (range $109.51 to $110.42). Read SEC document |
| February 02, 2015 Filed Feb 4, 2015 21:53 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 300 | $108.11 | $32,433.00 |
DisclosureSEC source: 0001209191-15-009472 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,012 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $108.11 (range $107.94 to $108.22). F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 02, 2015 Filed Feb 4, 2015 21:53 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,125 | $37.86 | $42,592.50 |
DisclosureSEC source: 0001209191-15-009472 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,312 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 26, 2015 Filed Jan 28, 2015 22:39 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 1,125 | $0.00 Strike: $48.74 | $0.00 |
DisclosureSEC source: 0001209191-15-007111 · doc4.xml · derivative · entry 5 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,750 Underlying: Common Stock · 1,125 shares Expires 2022-07-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vests in 16 quarterly installments from 07/25/2012. Read SEC document |
| January 26, 2015 Filed Jan 28, 2015 22:39 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 400 | $126.27 | $50,508.00 |
DisclosureSEC source: 0001209191-15-007111 · doc4.xml · nonDerivative · entry 3 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,187 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $126.27 (range $126.00 to $126.56). Read SEC document |
| January 26, 2015 Filed Jan 28, 2015 22:39 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 725 | $125.26 | $90,813.50 |
DisclosureSEC source: 0001209191-15-007111 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,587 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $125.26 (range $124.99 to $125.83). F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| January 26, 2015 Filed Jan 28, 2015 22:39 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,125 | $48.74 | $54,832.50 |
DisclosureSEC source: 0001209191-15-007111 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,312 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 13, 2015 Filed Jan 15, 2015 21:48 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 1,125 | $0.00 Strike: $51.75 | $0.00 |
DisclosureSEC source: 0001209191-15-004435 · doc4.xml · derivative · entry 6 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,250 Underlying: Common Stock · 1,125 shares Expires 2021-07-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option vests in 16 quarterly installments from 07/13/2011. Read SEC document |
| January 13, 2015 Filed Jan 15, 2015 21:48 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 400 | $123.05 | $49,220.00 |
DisclosureSEC source: 0001209191-15-004435 · doc4.xml · nonDerivative · entry 4 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,187 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $123.05 (range $122.87 to $123.57). Read SEC document |
| January 13, 2015 Filed Jan 15, 2015 21:48 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 300 | $122.28 | $36,684.00 |
DisclosureSEC source: 0001209191-15-004435 · doc4.xml · nonDerivative · entry 3 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,587 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $122.28 (range $121.83 to $122.62). Read SEC document |
| January 13, 2015 Filed Jan 15, 2015 21:48 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 425 | $120.61 | $51,259.25 |
DisclosureSEC source: 0001209191-15-004435 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,887 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $120.61 (range $120.36 to $120.93). F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| January 13, 2015 Filed Jan 15, 2015 21:48 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,125 | $51.75 | $58,218.75 |
DisclosureSEC source: 0001209191-15-004435 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,312 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 12, 2014 Filed Dec 16, 2014 21:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,100 | $120.48 | $132,528.00 |
DisclosureSEC source: 0001209191-14-075839 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,187 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $120.48 (range $120.28 to $120.84). Read SEC document |
| December 12, 2014 Filed Dec 16, 2014 21:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,713 | $119.82 | $205,251.66 |
DisclosureSEC source: 0001209191-14-075839 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,287 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $119.82 (range $119.20 to $120.19). F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| November 28, 2014 Filed Dec 1, 2014 22:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 3,867 | $0.00 Strike: $77.31 | $0.00 |
DisclosureSEC source: 0001209191-14-071981 · doc4.xml · derivative · entry 6 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,758 Underlying: Common Stock · 3,867 shares Expires 2024-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/05/2014. Read SEC document |
| November 28, 2014 Filed Dec 1, 2014 22:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 4,297 | $0.00 Strike: $83.36 | $0.00 |
DisclosureSEC source: 0001209191-14-071981 · doc4.xml · derivative · entry 5 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,453 Underlying: Common Stock · 4,297 shares Expires 2023-07-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 07/30/2013. Read SEC document |
| November 28, 2014 Filed Dec 1, 2014 22:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 8,164 | $119.85 | $978,455.40 |
DisclosureSEC source: 0001209191-14-071981 · doc4.xml · nonDerivative · entry 3 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. Read SEC document |
| November 28, 2014 Filed Dec 1, 2014 22:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 3,867 | $77.31 | $298,957.77 |
DisclosureSEC source: 0001209191-14-071981 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,164 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 28, 2014 Filed Dec 1, 2014 22:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 4,297 | $83.36 | $358,197.92 |
DisclosureSEC source: 0001209191-14-071981 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,297 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 05, 2014 Filed Nov 7, 2014 21:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 1,687 | $0.00 Strike: $45.11 | $0.00 |
DisclosureSEC source: 0001209191-14-067326 · doc4.xml · derivative · entry 6 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,188 Underlying: Common Stock · 1,687 shares Expires 2023-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/05/2013. Read SEC document |
| November 05, 2014 Filed Nov 7, 2014 21:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $114.29 | $11,429.00 |
DisclosureSEC source: 0001209191-14-067326 · doc4.xml · nonDerivative · entry 4 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. Read SEC document |
| November 05, 2014 Filed Nov 7, 2014 21:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 700 | $112.93 | $79,051.00 |
DisclosureSEC source: 0001209191-14-067326 · doc4.xml · nonDerivative · entry 3 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,100 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $112.93 (range $112.60 to $113.49). Read SEC document |
| November 05, 2014 Filed Nov 7, 2014 21:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 887 | $112.07 | $99,406.09 |
DisclosureSEC source: 0001209191-14-067326 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,800 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $112.07 (range $111.54 to $112.32). Read SEC document |
| November 05, 2014 Filed Nov 7, 2014 21:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,687 | $45.11 | $76,100.57 |
DisclosureSEC source: 0001209191-14-067326 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,687 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 03, 2014 Filed Nov 5, 2014 22:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 1,125 | $0.00 Strike: $37.86 | $0.00 |
DisclosureSEC source: 0001209191-14-066704 · doc4.xml · derivative · entry 7 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,625 Underlying: Common Stock · 1,125 shares Expires 2022-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/02/2012. Read SEC document |
| November 03, 2014 Filed Nov 5, 2014 22:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (right to buy) · Derivative | 937 | $0.00 Strike: $38.80 | $0.00 |
DisclosureSEC source: 0001209191-14-066704 · doc4.xml · derivative · entry 6 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 938 Underlying: Common Stock · 937 shares Expires 2021-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/03/2011. Read SEC document |
| November 03, 2014 Filed Nov 5, 2014 22:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 100 | $113.09 | $11,309.00 |
DisclosureSEC source: 0001209191-14-066704 · doc4.xml · nonDerivative · entry 4 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. Read SEC document |
| November 03, 2014 Filed Nov 5, 2014 22:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,962 | $111.97 | $219,685.14 |
DisclosureSEC source: 0001209191-14-066704 · doc4.xml · nonDerivative · entry 3 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,100 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $111.97 (range $111.66 to $112.29). Read SEC document |
| November 03, 2014 Filed Nov 5, 2014 22:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 1,125 | $37.86 | $42,592.50 |
DisclosureSEC source: 0001209191-14-066704 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Corp Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,062 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.